485841-52-9

Basic information

• Product Name: (S)-1,2-DIMETHYL-PIPERAZINE
• Synonyms: (S)-1,2-DIMETHYL-PIPERAZINE;(2S)-1,2-diMethylpiperazine;Piperazine, 1,2-diMethyl-, (2S)-;1,2-Dimethyl-(2S)-piperazine
• CAS NO: 485841-52-9
• Molecular Formula: C₆H₁₄N₂
• Molecular Weight: 114.191
• Mol File: 485841-52-9.mol

Chemical Properties

• Boiling Point: 147.0±8.0 °C(Predicted)
• Appearance: /
• Density: 0.855±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 9.31±0.40(Predicted)
• CAS DataBase Reference: (S)-1,2-DIMETHYL-PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-1,2-DIMETHYL-PIPERAZINE(485841-52-9)
• EPA Substance Registry System: (S)-1,2-DIMETHYL-PIPERAZINE(485841-52-9)

Safety Data

• Hazardous Substances Data: 485841-52-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(S)-1,2-Dimethyl-piperazine is used as a building block for the synthesis of various drugs and pharmaceuticals. It plays a crucial role in the development of antiviral, antifungal, and antiparasitic medications due to its unique molecular structure and properties.
Used in Chemical Reactions:
(S)-1,2-Dimethyl-piperazine is used as a solvent in chemical reactions, facilitating the process and improving the efficiency of the reactions.
Used in Polymer and Resin Production:
(S)-1,2-Dimethyl-piperazine is used as an additive in the production of polymers and resins, enhancing their properties and performance in various applications.

Upstream product

• 147081-29-6 (S)-3-methyl-piperazine-1-carboxylic acid tert-butyl ester 
• 1152110-42-3 tert-butyl (S)-3,4-dimethylpiperazine-1-carboxylate 

Downstream Products

• 623586-03-8 8-({5-chloro-2-[(3S)-3,4-dimethylpiperazin-1-yl]isonicotinoyl}amino)-1-(4-fluoro-phenyl)-4,5-dihydro-1H-benzo[g]indazole-3-carboxamide 
• 1402709-68-5 (S)-4-(3,4-dimethylpiperazin-1-yl)benzaldehyde 
• 1443977-70-5 (5R,6S)-5,6-bis(4-chlorophenyl)-2-[((2S,5R)-2-{[(3S)-3,4-dimethylpiperazin-1-yl]carbonyl}-5-ethylpyrrolidin-1-yl)carbonyl]-3-isopropyl-6-methyl-5,6-dihydroimidazo[2,1-b][1,3]thiazole 

Relevant articles and documents

SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS

Provided herein are compounds of the Formula I: (I) or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Optimization of imidazo[4,5- b ]pyridine-based kinase inhibitors: Identification of a dual FLT3/aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia

Optimization of the imidazo[4,5-b]pyridine-based series of Aurora kinase inhibitors led to the identification of 6-chloro-7-(4-(4-chlorobenzyl)piperazin- 1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine (27e), a potent inhibitor of Aurora kinases (Aurora-A Kd = 7.5 nM, Aurora-B K d = 48 nM), FLT3 kinase (Kd = 6.2 nM), and FLT3 mutants including FLT3-ITD (Kd = 38 nM) and FLT3(D835Y) (Kd = 14 nM). FLT3-ITD causes constitutive FLT3 kinase activation and is detected in 20-35% of adults and 15% of children with acute myeloid leukemia (AML), conferring a poor prognosis in both age groups. In an in vivo setting, 27e strongly inhibited the growth of a FLT3-ITD-positive AML human tumor xenograft (MV4-11) following oral administration, with in vivo biomarker modulation and plasma free drug exposures consistent with dual FLT3 and Aurora kinase inhibition. Compound 27e, an orally bioavailable dual FLT3 and Aurora kinase inhibitor, was selected as a preclinical development candidate for the treatment of human malignancies, in particular AML, in adults and children.